Effect Of Monotherapy And Combined Therapy With Thiazolidinedione Dpp 4 Inhibitors

Abstract

The American Diabetes Association has set a HbA1c objective of 7.0%, which appears excessive given the lack of a well-established HbA1c threshold for CVD risk. Hypoglycemia and weight gain are common adverse effects of the large doses of sulfonylureas and insulin needed to achieve a HbA1c of 6.0% or less. However, it has been shown that insulin sensitizers and GLP-1 analogs may keep -cells working without greatly raising the risk of hypoglycemia, therefore they may be titrated to maximal dose in order to bring down HbA1c levels below 6.0%. Finally, Weight loss and protection against the weight gain linked with TZDs are both possible thanks to GLP-1 analogs, but sulfonylurea and insulin treatment often cause weight gain.